Dr. Reddy's Laboratories Ltd. · NSE:DRREDDY

Dr. Reddy's Laboratories — 36th Annual J.P. Morgan Healthcare Conference 2018

25 slides from Dr. Reddy's Laboratories's conference presentation, Jan 9, 2018

  1. Slide 1: 36th Annual J.P. Morgan Healthcare Conference

    36th Annual J. P. Morgan Healthcare Conference January 9, 2018 Dr. Reddy’s Laboratories Limited Hyderabad, India BSE: 500124 | NSE: DRREDDY | NYSE: RDY

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and

  3. Slide 3: Contents

    Contents Our Purpose Company Overview Recent Business Highlights Growth Roadmap Optimistic Future 3

  4. Slide 4: Our Purpose

    Our Purpose We accelerate access to affordable and innovative medicines Because Good Health Can’t Wait.

  5. Slide 5: Our Purpose Guides Our Customer Value Proposition

    Our Purpose Guides Our Customer Value Proposition Leading to Specific Strategic Choices PURPOSE OUR PROMISES Bringing expensive medicine within reach We accelerate access to affordable medicines because Addressing unmet patient needs Good Health Helping patients manage disease better Can’t Wait. Ena

  6. Slide 6: Company Overview

    COMPANY OVERVIEW e O

  7. Slide 7: Multidimensional business model to sustain long-term growth

    Multidimensional business model to sustain long-term growth UNBRANDED BRANDED PROPRIETARY (US + EU) (EM + INDIA) PRODUCTS • Continued growth for mega Current • Maximize the base business • Monetize the complex/ limited brands through patient centric initiatives revenues through volume competition as

  8. Slide 8: Formulation manufacturing infrastructure and capabilities

    Formulation manufacturing infrastructure and capabilities DOSAGE FORM CAPABILITIES DETAILS 10 Facilities out of which Tablets, Capsules, Pellets, Oral Solids bi-layers, Modified / • 4 US FDA approved of which 2 are located in USA (22 bn pills annual) Extended release, ODTs • 3 MHRA approved 3 Facili

  9. Slide 9: Globalized R&D to Access the Right Talent

    Globalized R&D to Access the Right Talent to Solve Complex Scientific Challenges Complex Complex Injectable Chemistry Centre Centre of of Excellence Excellence Cambridge, UK Leiden, Netherlands Canada Germany UK USA Italy Product Development Complex Centers Generics & Hyderabad & Bangalore Proprieta

  10. Slide 10: Recent Business Highlights

    Recent Business Highlights 10

  11. Slide 11: Delivering affordable generic alternatives in Unbranded Markets

    Delivering affordable generic alternatives in Unbranded Markets 12 NEW PRODUCTS LAUNCHED IN NORTH AMERICA SO FAR THIS FISCAL Sevelamer Carbonate Tablets launched in the U.S. Market • Affordable alternative for complex, limited-competition product • Fourth limited-competition launch this fiscal year

  12. Slide 12: Biosimilars and small molecule Oncology assets fueling global expansion

    Biosimilars and small molecule Oncology assets fueling global expansion Successful launches of Oncology products in EM and EU • Colombia, Brazil, Algeria, Spain, Italy Reditux™ paving the way for the entry of upcoming Biosimilar assets in new markets • Currently approved in 17 countries and availabl

  13. Slide 13: Patient-centric Initiatives in Emerging Markets

    Making a difference through Patient-centric Initiatives in Emerging Markets Our first wave of patient-centric packaging has been received well  Four India Star awards for patient-centric packaging Push Tab feature in carton to (selected from 622 entries); now qualify for Asia star and Integrated fl

  14. Slide 14: Addressing unmet needs in Derma and Neurology

    Addressing unmet needs in Derma and Neurology Commercial Updates  First set of launches Zembrace™ and Sernivo™ ramping up well, continue to focus on accelerating the commercial business’ path to profitability  Promius Pharma recognized as an emerging R&D driven commercial organization in the neuro

  15. Slide 15: Our Quality Journey

    Our Quality Journey WE ARE COMMITTED TO EXCELLENCE IN QUALITY AND TO BEING THE BEST IN THE INDUSTRY U.S. FDA Audit Updates Sites Previously on Warning Letter CTO 5: Three observations in audit - Received EIR CTO 6: Two Observations in audit – EIR Awaited FTO 7 Sterile Plant: Received EIR: compliance

  16. Slide 16: Growth Roadmap

    Growth Roadmap e « ) )

  17. Slide 17: North America Generics: Growth driven by limited competition products

    North America Generics: Growth driven by limited competition products 2017 2021 • More than 50% of revenues to come from • Oral solid dosages account for almost 80% of Injectables, Topicals and other complex Portfolio the current revenues dosage forms • Injectables accounting for 20% of the revenues

  18. Slide 18: India & Emerging Markets: Growth driven by patient centric initiatives

    India & Emerging Markets : Growth driven by patient centric initiatives 2017 2021 • Portfolio augmentation and productivity improvement • Focus on mega brands • Step-up in Chronic and Super-specialty therapies expansion • India Strategic business development and M&A efforts • Improvement in new • Di

  19. Slide 19: Biologics: Maximizing value of current assets

    Biologics: Maximizing value of current assets in near to mid-term while pursuing global development EU/US approval enabling studies initiated for pegfilgrastim Rituximab and bevacizumab approval enabling studies for EU/US expected to be BIOLOGICS REVENUE HAS GROWN AT APPROX. initiated in next 4 - 6

  20. Slide 20: Biologics: Creating substantial value in long term

    Biologics: Creating substantial value in long term from new portfolio choices while driving R&D productivity 6 commercial products; > 50 filings across 14 major countries FY20 Product Portfolio 5 new products in clinical development Emerging Markets Revenue: ~ $150Mn FY20 Business Profile Developed

  21. Slide 21: Proprietary Products: Aspiring to build a $400 million business by FY22

    Proprietary Products: Aspiring to build a $400 million business by FY22 through a low-risk innovation model Specialty Dermatology Franchise • Established with the goal to address unmet needs of specific patient segments in • 3 Products approved; 1 asset commercialized Dermatology & Neurology and 2 l

  22. Slide 22: Key Priorities

    KEY PRIORITIES e « ) @

  23. Slide 23: 2018 Key Priorities

    2018 Key Priorities  Strengthening Manufacturing & Quality Create culture encouraging Transparency and Compliance Creating Leaner and Flexible cost structures  Focus on Manufacturing and R & D Network Rationalization, Improving Plant Operating Efficiency, R&D Productivity and Portfolio Optimizatio

  24. Slide 24: Good Health Can't Wait.

    Good Health Can’t Wait.

  25. Slide 25: Contacts

    Contacts Investor relations Media relations Saunak Savla Calvin Printer saunaks@drreddys.Com calvinprinter@drreddys.Com (Ph: +91-40-49002135) (Ph: +91-40-49002121) About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committ

Dr. Reddy's Laboratories — 36th Annual J.P. Morgan Healthcare Conference 2018 on 6ix